|
Accueil > Actualité
AstraZeneca: Enhertu granted orphan drug designation in US
(CercleFinance.com) - AstraZeneca and Daiichi Sankyo announce that Enhertu (trastuzumab deruxtecan) has received Orphan Drug Designation (ODD) in the United States for the treatment of patients with gastric cancer, including cancer of the gastroesophageal junction.
It is estimated that 27,600 new cases of gastric cancer will be diagnosed this year and the disease could lead to over 11,000 deaths in the United States in 2020. The Food and Drug Administration (FDA) grants ODD to drugs for the treatment, diagnosis or prevention of rare diseases or disorders that affect less than 200,000 people in the United States. The full results of DESTINY-Gastric-01 will be presented at the American Society of Clinical Oncology's Virtual Science Program 2020 ASCO20, from 29-31 May this year. Copyright (c) 2020 CercleFinance.com. All rights reserved. |
19/04/2024 18:06
Alstoma conclu un accord avec Knorr-Bremse 19/04/2024 17:30 Danoneen hausse après deux analyses positives 19/04/2024 16:35 TotalEnergiespartenariat avec OK Petroleum aux USA 19/04/2024 16:29 BAE Systemsmodernise une usine de munitions 19/04/2024 16:15 Netflixle titre trébuche après une publication contrastée 19/04/2024 16:09 Bayersigne un contrat de fourniture d'énergie renouvelables Tous les articles sociétés |
